Shares of Threshold Pharmaceuticals (NASDAQ: THLD) jumped up 15% today, bizarrely upon news that its competitor Celgene (CELG) announced a set of successful phase 3 results. In this video, Motley Fool health-care analyst David Williamson tells investors what was behind this counterintuitive pop, and why it could be an excellent indicator for some of Threshold's own trials.